157 related articles for article (PubMed ID: 23101960)
1. [Hormone replacement therapy in prostate cancer: side effects and their management].
Bonniol R; Timsit MO
Prog Urol; 2012 Nov; 22(14):881-5. PubMed ID: 23101960
[TBL] [Abstract][Full Text] [Related]
2. Management of the side effects of androgen deprivation therapy in men with prostate cancer.
Flaig TW; Glodé LM
Expert Opin Pharmacother; 2008 Nov; 9(16):2829-41. PubMed ID: 18937615
[TBL] [Abstract][Full Text] [Related]
3. Complications of androgen deprivation therapy in prostate cancer.
Schwandt A; Garcia JA
Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
5. [Management of the side effects of androgenic deprivation].
Lebret T; Méjean A
Prog Urol; 2008 Nov; 18 Suppl 7():S338-42. PubMed ID: 19070813
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome in prostate cancer: impact on risk and outcomes.
Karzai FH; Madan RA; Dahut WL
Future Oncol; 2016 Aug; 12(16):1947-55. PubMed ID: 27067408
[TBL] [Abstract][Full Text] [Related]
7. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy.
Nishiyama T; Kanazawa S; Watanabe R; Terunuma M; Takahashi K
Int J Urol; 2004 Sep; 11(9):735-41. PubMed ID: 15379937
[TBL] [Abstract][Full Text] [Related]
8. Management of complications of androgen deprivation therapy in the older man.
Mohile SG; Mustian K; Bylow K; Hall W; Dale W
Crit Rev Oncol Hematol; 2009 Jun; 70(3):235-55. PubMed ID: 18952456
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
10. Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects.
Walker LM; Tran S; Robinson JW
Clin Genitourin Cancer; 2013 Dec; 11(4):375-84. PubMed ID: 23891497
[TBL] [Abstract][Full Text] [Related]
11. Emerging cardiometabolic complications of androgen deprivation therapy.
Choong K; Basaria S
Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
[TBL] [Abstract][Full Text] [Related]
12. Promoting wellness for patients on androgen deprivation therapy: why using numerous drugs for drug side effects should not be first-line treatment.
Moyad MA; Roach M
Urol Clin North Am; 2011 Aug; 38(3):303-12. PubMed ID: 21798392
[TBL] [Abstract][Full Text] [Related]
13. [Metabolic impact of androgen deprivation therapy for prostate cancer].
Andrès E; Eschwege P; Lang H; Moreau JL; Peiffert D; Thiery-Vuillemin A; Kleinclauss F
Prog Urol; 2012 Sep; 22 Suppl 2():S39-47. PubMed ID: 23098789
[TBL] [Abstract][Full Text] [Related]
14. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
[TBL] [Abstract][Full Text] [Related]
15. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
16. Complications of androgen deprivation therapy for prostate cancer.
Holzbeierlein JM; McLaughlin MD; Thrasher JB
Curr Opin Urol; 2004 May; 14(3):177-83. PubMed ID: 15069309
[TBL] [Abstract][Full Text] [Related]
17. The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy.
Morote J; Gómez-Caamaño A; Alvarez-Ossorio JL; Pesqueira D; Tabernero A; Gómez Veiga F; Lorente JA; Porras M; Lobato JJ; Ribal MJ; Planas J;
J Urol; 2015 Jun; 193(6):1963-9. PubMed ID: 25541340
[TBL] [Abstract][Full Text] [Related]
18. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
19. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
Gomella LG
BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
[TBL] [Abstract][Full Text] [Related]
20. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
